Mercer Global Advisors
ACAD icon

Mercer Global Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Mercer Global Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Buy
+11,791
New +$259K ﹤0.01% 2814
2026
Q1 		– Sell
-9,620
Closed -$257K – 3218
2025
Q4 		$257K Buy
+9,620
New +$230K ﹤0.01% 2358

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mercer Global Advisors's ACAD Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 11,791 shares worth $298K. The stake represents ﹤0.01% of the portfolio and ranks #2814 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in ACAD as recently as Q4 2025.

Mercer Global Advisors first reported a position in ACAD in Q4 2025 and has held it in 2 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Mercer Global Advisors held 11,791 shares of Acadia Pharmaceuticals worth $298K as of Q2 2026.
  • Acadia Pharmaceuticals was a new Mercer Global Advisors position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2814 holding.
  • Mercer Global Advisors first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.